– CANADA, Calgary – XORTX Therapeutics Inc. (CSE: XRX | OTC: XRTXF), a biotechnology company focused on developing innovative therapies to treat progressive kidney disease, today announced the appointment of Jacqueline Le Saux to its board of directors.
“Jaqueline Le Saux brings to the XORTX board of directors an experienced legal and strategic perspective and a track record of success in value creation, risk management and ethics and corporate governance. We are pleased to gain the depth of talent and experience that she will bring to our board,”
About Jacqueline Le Saux
Jacqueline Le Saux is a seasoned Canadian health care legal executive who has held senior positions at large and small public and private life science companies. Jacqueline’s legal experience is focused on securities, pharmaceutical regulatory, and intellectual property law.
Jacqueline Le Saux commented, “It is an honor and privilege to join the XORTX board at this pivotal stage of the Company’s development. Kidney disease affects millions of patients around the world and I am pleased to be participating, through the XORTX board, in the development of therapies designed to address the unmet needs of these patients.”
About Jacqueline Le Saux
As a Vice President, Legal in both public and private companies Ms. Le Saux has led multiple financings, mergers, and acquisitions, and product licensing transactions, mitigating risk and executing strategies in the Canadian healthcare industry. Her broad industry experience spans big pharma to early and late-stage research and development, as well as consumer products and pharmaceutical manufacturing. Before entering the health care industry, she was a partner at a top-tier Canadian law firm, specializing in securities and corporate law. Jacqueline is now transitioning to the role of an independent Corporate Director.
About XORTX Therapeutics Inc.
XORTX Therapeutics Inc. is a biotechnology company with three clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease, XRx-101 for Coronavirus / COVID-19 infection, and XRx-225, a pre-clinical stage program for Type 2 Diabetic Nephropathy. The Company has intellectual property rights and has established proof of concept through independent clinical studies. XORTX is working to advance its clinical development-stage products that target xanthine oxidase to inhibit the production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and the future of patients suffering from kidney disease.
For more information: https://www.xortx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.